サマリー

市場の展望
Triton Market Researchのレポートでは、ヨーロッパのセルライト治療市場は、予測年2023年から2030年の間に、収益が9.51％の複合年間成長率で進むと予想されているとほのめかしています。ドイツ、イタリア、英国、スペイン、フランス、北欧諸国、および欧州の残りの地域が調査対象です。
フランスでは、人口の約40％が肥満と診断されており、様々な治療法への需要が高まっています。さらに、老人の人口が多いことも特徴です。このため、近年、セルライト減少治療に対するニーズが高まっています。さらに、業界筋によると、形成外科医の利用可能性も過去数年間で増加している。したがって、美意識の高まりにより、皮膚の施術に対する需要が増加し、セルライト治療市場を成長軌道に乗せることが期待されます。
さらに、技術の進歩により美容施術が強化され、イタリアでは様々な消費者を魅了しています。また、革新的な皮膚治療を求める外国人患者の増加も見られます。この点で、高周波療法は大きな注目を浴びています。低侵襲手術の急増は、医療観光客の流入に拍車をかけている。したがって、医療観光客と美容意識の高まりは、イタリア全土のセルライト治療市場に新たな道を開くことになります。

競争展望
セルライト治療市場の注目すべき企業には、ジョンソン・エンド・ジョンソン、Bausch Health Companies Inc、Cutera Inc、Galderma SA、Candela Medical Corporationがあります。

ページTOPに戻る

目次

TABLE OF CONTENTS
1. EUROPE CELLULITE TREATMENT MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1.PARENT MARKET ANALYSIS
2.2.IMPACT ANALYSIS ON THE CELLULITE TREATMENT MARKET
2.2.1.COVID-19 IMPACT ON THE CELLULITE TREATMENT MARKET
2.2.2.UKRAINE-RUSSIA WAR IMPACT ON THE CELLULITE TREATMENT MARKET
2.3.PORTER’S FIVE FORCES ANALYSIS
2.3.1.THREAT OF NEW ENTRANTS
2.3.2.THREAT OF SUBSTITUTES
2.3.3.BARGAINING POWER OF BUYERS
2.3.4.BARGAINING POWER OF SUPPLIERS
2.3.5.THREAT OF COMPETITIVE RIVALRY
2.4.MARKET MATURITY ANALYSIS
2.5.INDUSTRY COMPONENTS
2.5.1.RESEARCH AND DEVELOPMENT
2.5.2.MANUFACTURING OF PRODUCT
2.5.3.DISTRIBUTION
2.5.4.POST-SALES MONITORING
2.6.REGULATORY FRAMEWORK
2.7.KEY BUYING IMPACT ANALYSIS
2.7.1.PRICE
2.7.2.BRAND NAME
2.7.3.USABILITY
2.8.KEY MARKET STRATEGIES
2.8.1.COLLABORATIONS
2.8.2.PRODUCT LAUNCHES
2.8.3.MERGERS & ACQUISITIONS
2.8.4.BUSINESS DIVESTITURES & EXPANSIONS
2.9.MARKET DRIVERS
2.9.1.GROWING PREVALENCE OF OBESITY
2.9.2.RAPIDLY GROWING MEDICAL TOURISM SECTOR
2.9.3.RISING DEMAND FOR AESTHETIC PROCEDURES
2.10.MARKET CHALLENGES
2.10.1.LACK OF KNOWLEDGE REGARDING CELLULITE TREATMENT
2.10.2.HIGH PRICE OF ADVANCED CELLULITE TREATMENT
2.10.3.RISKS ASSOCIATED POST-TREATMENT
2.11.MARKET OPPORTUNITIES
2.11.1.RISING BEAUTY CONSCIOUSNESS
2.11.2.INCREASING TREND OF ANTI-CELLULITE MASSAGE
2.11.3.GROWING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES
2.11.4.RISING POPULARITY OF RADIOFREQUENCY THERAPY FOR CELLULITE TREATMENT
2.11.5.ADVANCEMENTS IN TECHNOLOGIES AND NEW PRODUCT LAUNCHES
2.12.ANALYST PERSPECTIVE
3. EUROPE CELLULITE TREATMENT MARKET – BY CELLULITE TYPE
3.1.SOFT CELLULITE
3.2.HARD CELLULITE
3.3.EDEMATOUS CELLULITE
4. EUROPE CELLULITE TREATMENT MARKET – BY PROCEDURE TYPE
4.1.NON-INVASIVE
4.2.MINIMALLY INVASIVE
4.3.TOPICAL
5. EUROPE CELLULITE TREATMENT MARKET – BY END-USER
5.1.HOSPITALS
5.2.CLINICS AND BEAUTY CENTERS
5.3.OTHER END-USERS
6. EUROPE CELLULITE TREATMENT MARKET – BY COUNTRY OUTLOOK
6.1.COUNTRY ANALYSIS
6.1.1.UNITED KINGDOM
6.1.1.1.UNITED KINGDOM CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.2.GERMANY
6.1.2.1.GERMANY CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.3.FRANCE
6.1.3.1.FRANCE CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.4.ITALY
6.1.4.1.ITALY CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.5.SPAIN
6.1.5.1.SPAIN CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.6.NORDIC COUNTRIES
6.1.6.1.NORDIC COUNTRIES CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.7.REST OF EUROPE
6.1.7.1.REST OF EUROPE CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
7. COMPETITIVE LANDSCAPE
7.1.JOHNSON & JOHNSON
7.1.1.OVERVIEW
7.1.2.PRODUCT PORTFOLIO
7.1.3.KEY STRENGTHS
7.1.4.KEY CHALLENGES
7.2.ABBVIE INC
7.2.1.OVERVIEW
7.2.2.PRODUCT PORTFOLIO
7.2.3.KEY STRENGTHS
7.2.4.KEY CHALLENGES
7.3.BAUSCH HEALTH COMPANIES INC
7.3.1.OVERVIEW
7.3.2.PRODUCT PORTFOLIO
7.3.3.KEY STRENGTHS
7.3.4.KEY CHALLENGES
7.4.CUTERA INC
7.4.1.OVERVIEW
7.4.2.PRODUCT PORTFOLIO
7.4.3.KEY STRENGTHS
7.4.4.KEY CHALLENGES
7.5.INCELER MEDIKAL
7.5.1.OVERVIEW
7.5.2.PRODUCT PORTFOLIO
7.5.3.KEY STRENGTHS
7.5.4.KEY CHALLENGES
7.6.ZIMMER MEDIZINSYSTEME GMBH
7.6.1.OVERVIEW
7.6.2.PRODUCT PORTFOLIO
7.6.3.KEY STRENGTHS
7.6.4.KEY CHALLENGES
7.7.GALDERMA SA
7.7.1.OVERVIEW
7.7.2.PRODUCT PORTFOLIO
7.7.3.KEY STRENGTHS
7.7.4.KEY CHALLENGES
7.8.SIENTRA INC
7.8.1.OVERVIEW
7.8.2.PRODUCT PORTFOLIO
7.8.3.KEY STRENGTHS
7.8.4.KEY CHALLENGES
7.9.ENDO INTERNATIONAL PLC
7.9.1.OVERVIEW
7.9.2.PRODUCT PORTFOLIO
7.9.3.KEY STRENGTHS
7.9.4.KEY CHALLENGES
7.10.CANDELA MEDICAL CORPORATION
7.10.1.OVERVIEW
7.10.2.PRODUCT PORTFOLIO
7.10.3.KEY STRENGTHS
7.10.4.KEY CHALLENGES
8. RESEARCH METHODOLOGY & SCOPE
8.1.RESEARCH SCOPE & DELIVERABLES
8.1.1.OBJECTIVES OF STUDY
8.1.2.SCOPE OF STUDY
8.2.SOURCES OF DATA
8.2.1.PRIMARY DATA SOURCES
8.2.2.SECONDARY DATA SOURCES
8.3.RESEARCH METHODOLOGY
8.3.1.EVALUATION OF THE PROPOSED MARKET
8.3.2.IDENTIFICATION OF DATA SOURCES
8.3.3.ASSESSMENT OF MARKET DETERMINANTS
8.3.4.DATA COLLECTION
8.3.5.DATA VALIDATION & ANALYSIS

TABLE LIST
TABLE 1: EUROPE CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 7: EUROPE CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2023-2030 (IN $ MILLION)
TABLE 9: EUROPE CELLULITE TREATMENT MARKET, BY END-USER, 2023-2030 (IN $ MILLION)
TABLE 10: EUROPE CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

FIGURE LIST
FIGURE 1: MARKET MATURITY ANALYSIS
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: KEY BUYING IMPACT ANALYSIS
FIGURE 4: EUROPE CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2022 & 2030 (IN %)
FIGURE 5: EUROPE CELLULITE TREATMENT MARKET, BY SOFT CELLULITE, 2023-2030 (IN $ MILLION)
FIGURE 6: EUROPE CELLULITE TREATMENT MARKET, BY HARD CELLULITE, 2023-2030 (IN $ MILLION)
FIGURE 7: EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2022 & 2030 (IN %)
FIGURE 8: EUROPE CELLULITE TREATMENT MARKET, BY NON-INVASIVE, 2023-2030 (IN $ MILLION)
FIGURE 9: EUROPE CELLULITE TREATMENT MARKET, BY MINIMALLY INVASIVE, 2023-2030 (IN $ MILLION)
FIGURE 10: EUROPE CELLULITE TREATMENT MARKET, BY TOPICAL, 2023-2030 (IN $ MILLION)
FIGURE 11: EUROPE CELLULITE TREATMENT MARKET, BY END-USER, 2022 & 2030 (IN %)
FIGURE 12: EUROPE CELLULITE TREATMENT MARKET, BY HOSPITALS, 2023-2030 (IN $ MILLION)
FIGURE 13: EUROPE CELLULITE TREATMENT MARKET, BY CLINICS AND BEAUTY CENTERS, 2023-2030 (IN $ MILLION)
FIGURE 14: EUROPE CELLULITE TREATMENT MARKET, BY OTHER END-USERS, 2023-2030 (IN $ MILLION)
FIGURE 15: EUROPE CELLULITE TREATMENT MARKET, COUNTRY OUTLOOK, 2022 & 2030 (IN %)
FIGURE 16: UNITED KINGDOM CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 17: GERMANY CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 18: FRANCE CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 19: ITALY CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 20: SPAIN CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 21: NORDIC COUNTRIES CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 22: REST OF EUROPE CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)

ページTOPに戻る

図表リスト

TABLE LIST
TABLE 1: EUROPE CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 7: EUROPE CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2023-2030 (IN $ MILLION)
TABLE 9: EUROPE CELLULITE TREATMENT MARKET, BY END-USER, 2023-2030 (IN $ MILLION)
TABLE 10: EUROPE CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)